Kaposi's sarcoma in the early post-transplant period in a kidney transplant recipient.

Nefrologia 2013;33(6):849-67 861 To the Editor: The chronic use of immunosuppressive agents is associated with the long-term risk of a wide variety of malignancies, including Kaposi’s sarcoma (KS), in renal transplant recipients compared with those of the general population. KS occurs after transplantation of 5 to 21 months and more commonly in males. The dose reduction or cessation of immunosuppresive drugs is the mainly approach for the treatment of KS in renal transplant patients, and switching calcineurin inhibitors to mammalian target of rapamycin inhibitors should be considered. Herein, we aimed to announce a 30-yearold male kidney transplant patient who had developed KS despite use of sirolimus after transplantation of 4 month and to the best of our knowledge this is the earliest onset case of KS after kidney transplantation.